|
|
No association between Ljungan virus seropositivity and the beta-cell damaging process in the Finnish Type 1 Diabetes Prediction and Prevention Study cohort |
|---|---|
| Author: | Jääskeläinen, Anne J.1; Nurminen, Noora2; Kolehmainen, Pekka3; |
| Organizations: |
1Department of Virology, Helsinki University and Helsinki University Hospital (HUSLAB), Finland 2Department of Virology, School of Medicine, University of Tampere, Tampere, Finland 3Department of Virology, University of Turku, Turku, Finland
4Department of Physiology, Institute of Biomedicine, University of Turku, Turku, Finland
5Department of Pediatrics, Turku University Hospital, Turku, Finland 6Immunogenetics Laboratory, University of Turku and Turku University Hospital, Turku, Finland 7Department of Pediatrics, PEDEGO Research Unit, Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland 8Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland 9Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland 10Folkhälsan Research Center, Helsinki, Finland 11Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland 12Fimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland 13Faculty of Veterinary Medicine, Department of Veterinary Biosciences, University of Helsinki, Finland |
| Format: | article |
| Version: | accepted version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 1.1 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2020101584184 |
| Language: | English |
| Published: |
Wolters Kluwer,
2019
|
| Publish Date: | 2020-10-15 |
| Description: |
AbstractBackground: Ljungan virus (LV) has not confirmed to associate with any human disease, but a possible connection with type 1 diabetes has been suggested. LV is a rodent-borne picornavirus that induces a diabetes-like condition in rodents. Approximately 30% of adults and 60% of children are seropositive in Finland. The Finnish Type 1 Diabetes Prediction and Prevention study enabled the use of very well characterized sample panels from children seroconverted to positivity for multiple islet autoantibodies during their prospective observation from birth; in addition, samples from age, sex, human leukocyte antigen (HLA), and residence area matched control children. Methods: We analyzed LV IgG seroprevalence in 102 case children (65 had also developed type 1 diabetes), in addition to nondiabetic control children. LV and human parechovirus (HPeV) immunofluorescence assays were used to analyze LV and HPeV-specific IgG from 102 plasma samples taken at the time of islet autoantibody appearance and from 204 samples from the matched control children. Results: Altogether 46.1% of the case and 50.7% of the control children were positive for LV IgG (odds ratio 0.8; 95% confidence interval, 0.47–1.36; P = 0.416) and 67.6% versus 79.8% were positive for HPeV IgG, respectively (odds ratio 0.49, 0.27–0.9, P = 0.023). Conclusions: Thus, no risk associations between LV or HPeV-specific IgG and islet autoimmunity were observed. However, a trend for significantly higher prevalence of HPeV antibodies in control children (P = 0.023) suggests a possible protective association of this virus with islet autoimmunity. see all
|
| Series: |
Pediatric infectious disease journal |
| ISSN: | 0891-3668 |
| ISSN-E: | 1532-0987 |
| ISSN-L: | 0891-3668 |
| Volume: | 38 |
| Issue: | 3 |
| Pages: | 314 - 316 |
| DOI: | 10.1097/INF.0000000000002201 |
| OADOI: | https://oadoi.org/10.1097/INF.0000000000002201 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3121 General medicine, internal medicine and other clinical medicine |
| Subjects: | |
| Copyright information: |
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. |